Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.
Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
Di Leo, E;Patruno, C;Foti, C;Macchia, L;Napolitano, M;Di Bona, D;Romita, P;Carbonara, M;
2020-01-01
Abstract
Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
bjd.19577.pdf
non disponibili
Descrizione: articolo principale
Tipologia:
Documento in Pre-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
3.89 MB
Formato
Adobe PDF
|
3.89 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
